GBI Research
GBI Research Market Research Reports
| Title | published | price | |
|---|---|---|---|
Respiratory Syncytial Virus and Human Parainfluenza Virus 3 Infections Drug Development Pipeline Review, 2018By GBI Research
This report provides an overview of the pipeline landscape for the respiratory tract infections respiratory syncytial virus (RSV) and human parainfluenza virus 3 (HPIV-3).It provides comprehensive information on the therapeutics under ... |
30-Mar-2018 | $3995 | |
Non Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Drug Development Pipeline Review, 2018By GBI Research
This report provides an overview of the non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players acti ... |
22-Mar-2018 | $3995 | |
Fungal Foot Infections Drug Development Pipeline Review, 2018By GBI Research
Summary This report provides an overview of the fungal foot infection pipeline landscape. It provides comprehensive information on the therapeutics under development for onychomycosis (Tinea unguium) and athlete's foot (Ti ... |
22-Mar-2018 | $3995 | |
Rheumatoid Arthritis Therapeutics in Asia-Pacific Markets to 2023 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFsBy GBI Research
Summary Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many year ... |
01-Mar-2018 | $4995 | |
Global Neurodegenerative Diseases Drugs Market to 2023 - MS Set to Dominate with Tecfidera and Ocrevus, as Disease-Modifying Pipeline Therapies for Alzheimer’s Disease and SMA Show Clinical and Commercial PotentialBy GBI Research
Summary Neurodegenerative diseases are becoming increasingly prevalent due to an aging population, but this diverse therapy area remains largely untreatable with current therapies. Neurodegenerative diseases are ch ... |
07-Feb-2018 | $4995 | |
Antibacterial Therapeutics - High levels of Pipeline Innovation Focused on the Increasing Unmet Need Associated with Antibiotic ResistanceBy GBI Research
Summary Antibacterial resistance is currently believed to be responsible for over 700,000 deaths each year. As antibiotic resistance increases, due to the overuse and misuse of antibiotics, the number of avoidable deaths i ... |
01-Feb-2018 | $6995 | |
Frontier Pharma: Women's Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class PipelineBy GBI Research
Frontier Pharma: Women's Health - An Expanding Therapy Area, with Endometriosis Therapies Prominent among the First-in-Class Pipeline Summary The women's health therapy area covers medical disorders that affect females only, ... |
01-Feb-2018 | $6995 | |
Uveitis Therapeutics in Asia-Pacific Markets to 2023 - Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the MarketBy GBI Research
Uveitis Therapeutics in Asia-Pacific Markets to 2023 - Increasing Prevalence, Continued Uptake of Biologics and Novel Pipeline Drugs to Drive the Market Summary Uveitis refers to inflammation of the uvea, the middle vascular ... |
01-Feb-2018 | $4995 | |
Lower Female Reproductive System Cancers Drug Development Pipeline Review, 2017By GBI Research
This report provides an overview of the Lower Female Reproductive System Cancers pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Cervic ... |
26-Jan-2018 | $3995 | |
Bladder and Ureter Cancer Drug Development Pipeline Review, 2017By GBI Research
This report provides an overview of the bladder and ureter pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for these two indications, and f ... |
22-Jan-2018 | $3995 | |
- + 1 888 391 5441
- [email protected]
